To improve the in vivo antitumor effect of TRAIL by increasing its tumor accumulation, tumor-homing molecules, such as antibodies or peptides recognizing some tumor-associated antigens, were fused to TRAIL to produce tumor-homing TRAIL variants (Tao et al., 2017; Dianat-Moghadam et al., 2020; Snajdauf et al., 2021). The gene discussed is TNFSF10; the disease is neoplasm.